Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Updated . What changed?
Prelude Therapeutics Inc is a biotechnology business based in the US. Prelude Therapeutics shares (PRLD) are listed on the NASDAQ and all prices are listed in US Dollars. Prelude Therapeutics employs 51 staff and has a market cap (total outstanding shares value) of USD$1.4 billion.
|Latest market close||USD$31|
|52-week range||USD$23.693 - USD$50.19|
|50-day moving average||USD$35.5463|
|200-day moving average||USD$35.5463|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-53.36%|
|1 month (2020-12-15)||-55.66%|
|3 months (2020-10-15)||-8.85%|
|6 months (2020-07-11)||N/A|
|1 year (2020-01-11)||N/A|
|2 years (2019-01-11)||N/A|
|3 years (2018-01-11)||N/A|
|5 years (2016-01-11)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.4 billion|
TTM: trailing 12 months
There are currently 5,757 Prelude Therapeutics shares held short by investors – that's known as Prelude Therapeutics's "short interest". This figure is up from 0 last month.
There are a few different ways that this level of interest in shorting Prelude Therapeutics shares can be evaluated.
Prelude Therapeutics's "short interest ratio" (SIR) is the quantity of Prelude Therapeutics shares currently shorted divided by the average quantity of Prelude Therapeutics shares traded daily (recently around 575700). Prelude Therapeutics's SIR currently stands at 0.01. In other words for every 100,000 Prelude Therapeutics shares traded daily on the market, roughly 10 shares are currently held short.
To gain some more context, you can compare Prelude Therapeutics's short interest ratio against those of similar companies.
However Prelude Therapeutics's short interest can also be evaluated against the total number of Prelude Therapeutics shares, or, against the total number of tradable Prelude Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Prelude Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Prelude Therapeutics shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Prelude Therapeutics shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Prelude Therapeutics.
Find out more about how you can short Prelude Therapeutics stock.
We're not expecting Prelude Therapeutics to pay a dividend over the next 12 months.
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.